دورية أكاديمية
أعرض في EDS

Prevalence, outcomes and associated factors of SARS-CoV-2 infection in psoriasis patients of Southwest China: a cross-sectional survey.

التفاصيل البيبلوغرافية
العنوان: Prevalence, outcomes and associated factors of SARS-CoV-2 infection in psoriasis patients of Southwest China: a cross-sectional survey.
المؤلفون: Zou Y; Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China., Xu J; Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China., Chen AJ; Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China., Huang K; Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China., Zhu SM; Department of Dermatology, People's Hospital Affiliated of Chongqing Three Gorges Medical College, Chongqing, China., Li JJ; Department of Dermatology, Chongqing University Qianjiang Hospital, Chongqing, China., He J; Department of Dermatology, The People's Hospital of Kaizhou District, Chongqing, China., Li JZ; Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China., Xiong JX; Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China., Fan YK; Department of Dermatology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China., Liu C; Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China., Pan Y; Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China., Wang P; Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. wang_ping@hospital.cqmu.edu.cn.
المصدر: Scientific reports [Sci Rep] 2024 Mar 15; Vol. 14 (1), pp. 6331. Date of Electronic Publication: 2024 Mar 15.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: COVID-19*/epidemiology , Psoriasis*/complications , Psoriasis*/epidemiology, Humans ; Cross-Sectional Studies ; Prevalence ; SARS-CoV-2 ; COVID-19 Vaccines ; China/epidemiology ; Disease Progression
مستخلص: In this study we aimed to investigate the prevalence of SARS-CoV-2 infection in psoriasis patients, and outcomes of SARS-CoV-2 infection and associated risk factors. A cross-sectional survey was conducted from February 2023 to March 2023. Information was obtained with online questionnaire about psoriasis patients on demographic characteristics, clinical characteristics, SARS-CoV-2 infection and outcomes, vaccination, and routine protection against COVID-19. Logistic regression analysis was used to explore risk factors with SARS-CoV-2 infection and exacerbation of psoriasis. A total of 613 participants were recruited. 516 (84.2%) were infected, and associated factors were sex, working status, routine protection against COVID-19, COVID-19 vaccination, impaired nail, infection exacerbate psoriasis, and severity of psoriasis. Among the patients infected with SARS-CoV-2, 30 (5.8%) required hospitalization, 122 (23.6%) had psoriasis exacerbation due to SARS-CoV-2 infection, and associated factors were subtype of psoriasis, discontinuation of psoriasis treatment during SARS-CoV-2 infection, response following COVID-19 vaccination, and severity of psoriasis. Booster dose vaccination contributed a low probability of COVID-19 sequelae. COVID-19 vaccine's effectiveness was unsatisfactory, while booster dose vaccination reduced the occurrence of COVID-19 sequelae in psoriasis patients of Southwest China. Patients treated with psoriasis shown to be safe, without a higher incidence of SARS-CoV-2 infection or COVID-19hospitalization compared to untreated patients. Stopping treatment during SARS-CoV-2 infection led to psoriasis exacerbation, so psoriasis treatment could be continued except severe adverse reaction.
(© 2024. The Author(s).)
References: N Engl J Med. 2020 Feb 20;382(8):727-733. (PMID: 31978945)
Ann Intern Med. 2021 Nov;174(11):1572-1585. (PMID: 34461029)
Nature. 2021 Oct;598(7881):398-399. (PMID: 34650240)
Dermatol Ther. 2021 Nov;34(6):e15113. (PMID: 34453380)
Lancet Reg Health West Pac. 2023 Jan 31;30:100702. (PMID: 36741798)
J Med Virol. 2023 Mar;95(3):e28601. (PMID: 36815498)
Lancet Respir Med. 2023 Feb;11(2):132. (PMID: 36535298)
Ther Adv Chronic Dis. 2022 May 20;13:20406223221099333. (PMID: 35620185)
J Invest Dermatol. 2018 Aug;138(8):1726-1735. (PMID: 29505759)
J Inflamm Res. 2021 Nov 27;14:6265-6273. (PMID: 34866925)
N Engl J Med. 2021 Apr 22;384(16):1576-1577. (PMID: 33596348)
Nature. 2020 Oct;586(7830):594-599. (PMID: 32998157)
JAMA Dermatol. 2015 Sep;151(9):961-9. (PMID: 25970800)
Nat Med. 2023 Mar;29(3):579-582. (PMID: 36638825)
J Cosmet Dermatol. 2021 Oct;20(10):3098-3102. (PMID: 34365714)
Cell. 2020 May 28;181(5):1016-1035.e19. (PMID: 32413319)
Nature. 2020 Aug;584(7820):262-267. (PMID: 32512578)
J Med Virol. 2023 Mar;95(3):e28616. (PMID: 36840408)
Br J Dermatol. 2022 May;186(5):773-781. (PMID: 34939663)
Clin Infect Dis. 2022 Aug 24;75(1):e545-e551. (PMID: 35380632)
Lancet. 2021 Apr 3;397(10281):1301-1315. (PMID: 33812489)
Int J Mol Sci. 2022 Jun 23;23(13):. (PMID: 35805960)
J Eur Acad Dermatol Venereol. 2019 Apr;33(4):643-647. (PMID: 30924245)
J Neuroimmune Pharmacol. 2021 Mar;16(1):38-47. (PMID: 33405098)
J Dermatolog Treat. 2023 Dec;34(1):2161297. (PMID: 36545844)
Lancet Infect Dis. 2023 Apr;23(4):403-404. (PMID: 36803917)
Lancet Respir Med. 2020 Apr;8(4):e20. (PMID: 32171067)
Nat Commun. 2023 Apr 10;14(1):2009. (PMID: 37037803)
J Dermatol. 2021 Jun;48(6):894-901. (PMID: 33894071)
J Infect Public Health. 2023 Jan;16(1):4-14. (PMID: 36446204)
Curr Dermatol Rep. 2022;11(4):263-288. (PMID: 36310766)
Am J Clin Dermatol. 2022 Nov;23(6):775-799. (PMID: 36048409)
Trends Immunol. 2021 Jan;42(1):18-30. (PMID: 33277181)
BMJ. 2021 Jul 26;374:n1648. (PMID: 34312178)
Front Immunol. 2022 Oct 21;13:1046352. (PMID: 36389759)
Int J Environ Res Public Health. 2022 Sep 29;19(19):. (PMID: 36231717)
Dermatol Ther. 2020 Nov;33(6):e13858. (PMID: 32686245)
Clin Rev Allergy Immunol. 2023 Feb;64(1):90-107. (PMID: 35044620)
Int J Mol Sci. 2019 Mar 23;20(6):. (PMID: 30909615)
J Clin Epidemiol. 1996 Dec;49(12):1373-9. (PMID: 8970487)
معلومات مُعتمدة: 82103733 National Natural Science Foundation of China; 2022QNXM048 Joint project of Chongqing Health Commission and Science and Technology Bureau
المشرفين على المادة: 0 (COVID-19 Vaccines)
تواريخ الأحداث: Date Created: 20240316 Date Completed: 20240318 Latest Revision: 20240318
رمز التحديث: 20240318
مُعرف محوري في PubMed: PMC10943245
DOI: 10.1038/s41598-024-54424-y
PMID: 38491005
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-024-54424-y